Skip to main content
Premium Trial:

Request an Annual Quote

Mayo Clinic Inks Biosample Management Deal With ISpecimen

NEW YORK (GenomeWeb) – Biological specimen provider ISpecimen announced today that it has signed an agreement to exclusively manage serum samples and associated data for the Mayo Clinic Center for Individualized Medicine's Cancer Serum Biobank.

The biobank holds roughly 130,000 frozen serum samples collected between 1975 and 1990 from about 17,000 unique Mayo Clinic patients covering 85 malignant and benign cancers, as well as normal controls. It also includes patient diagnosis and treatment data.

ISpecimen said it will manage the serum inventory and data through its cloud-based technology platform, helping to match researchers to the appropriate samples for their studies. Additional terms of the arrangement were not disclosed.

"Despite holding thousands of sought-after samples, the biorepository is underutilized by external researchers," Stephen Thibodeau, director of the biorepositories program at the Center for Individualized Medicine, said in a statement. "ISpecimen presented an opportunity for us to work with them to efficiently move these specimens into the hands of many more scientists studying cancer and related conditions."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.